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Derivatives  of Lavendamycin,  an  antitumor  antibiotic  natural  product,  were 
synthesized via short and efficient methods.  Pictet-Spengler condensation of 7N­
butryamido-2-formylquinoline-5,8-dione  (11)  with  neutralized  tryptophan  amide 
afforded  7N-butryamidodemethyllavendamycin  (13).  7N-Butyramdio-2­
formylquinoline-5,8-dione (11) was prepared by the oxidation of 7N-butryamdio­
2-methylquinoline-5,8-dione (8).  Novel  7-methoxy-2-formylquinoline-5,8-dione 
(19)  was  prepared  via  oxidative  deprotection  of  2-(  dimethoxymethyl)-7­
methoxyquinoline-5,8-dione (18).  A newly synthesized lavendamycin derivative 
is reported in compound 20. 2 
Total Synthesis of Lavendamycin Derivatives 
Edward A. Hall 
Department afChemistry, Ball State University, Muncie, Indiana 47306 
Derivatives  of Lavendamycin,  an  antitumor  antibiotic  natural  product,  were 
synthesized via short and efficient  methods.  Pictet-Spengler condensation of 
7N-butryamido-2-formylquinoline-5,8-dione  (11)  with  neutralized  tryptophan 
amide afforded 7  N-butryamidodemethyllavendamycin (13).  7N-Butyramdio-2­
formylquinoline-5,8-dione  (11)  was  prepared  by  the  oxidation  of  7N­
butryamdio-2-methylquinoline-5,8-dione  (8).  Novel  7 -methoxy-2­
formylquinoline-5,8-dione  (19)  was prepared via oxidative deprotection of  2­
(dimethoxymethyl)-7-methoxyquinoline-5,8-dione  (18).  A  newly  synthesized 
lavendamycin derivative is reported in compound 20. 
Introduction 
Lavendamycin is an antitumor antibiotic that was first isolated by BaUtz et al. I  in 1981  from the 
fermentation broth of Streptomyces lavendulae and the structure was determined by Doyle and co­
workers  in  1984?  Along  with Streptonigrin,  another tumor suppressing compound isolated from 
Streptomyces,  Lavendamycin  has  shown  significant  biological  activity.  However,  both  the 
streptonigrin and the parent lavendamycin were found to  be  highly toxic which diverges from the 
goals of  most modem cancer drug discovery.  A drug must be synthesized to both have high cytotoxic 
activity as well as minimal toxicity to the body.  Lavendamycin and its derivatives have achieved this 
goal through selective activity on molecular targets within malignant cells.  Lavendamycin analogues 
with  various  substituents  have  been  synthesized  as  NAD(P)H:quinine  oxidoreductase  I  (NQ01)­
directed  antitumor agents.  Marked  elevations  in NQO  1  activity  and  mRNA content  in primary 
tumors from lung, liver, colon, breast, lung, liver, brain, and colorectal tumors suggest that antitumor 
compounds  that  are  bioactivated  by  NQOl  may  be  selectively  toxic  to  those  tumors.
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Figure 1: Molecular Structure of Lavendamycin  Figure 2: Lavendamycin Derivatives 
Lavendamycin is activated by docking with NQOl thus selectively attacking cancer cells.  NQOl 
catalyzes an NAD(P)H dependent, two-electron reduction of quinones.  Due to this type of catalysis, 3 
the 7-amino-~uinoline-5,8-dione moiety is essential for biological activity as had been shown in intial 
SAR studies. 
In  addition  to  tumor  reduction,  lavendamycin  has  been  studied  for  its  potent  HIV  reverse 
transcriptase inhibitor activity.
5  As with many other treatments for  HIV, the effect of the compound 
is  enhanced  synergistically  with  other  drugs  taken  together.  A  wide  range  of lavendamycin 
derivatives have been tested in combination with Azidothymidine Triphosphate (AZT  -TP),  another 
mainstay  anti-HIV  treatment.  This  synergistic  effect  was  shown  to  the  greatest  extent  with  low 
concentrations of  (AZT  -TP) and with the few water soluble derivatives that have been synthesized. 
The first  reported total  synthesis of lavendamycin methyl  ester was  synthesized by  Kende  and 
Ebetin0
6  in  1984.  The  synthesis  was  performed  via  Bischler-Napieralski  condensation  of a 
substituted  quinaldic  acid  with  ~-methyltryptophan  methyl  ester  followed  by  cyclization  and 
functionalization of  the dione ring.  A second synthesis was reported by Boger et a1.
7 in 1985 using by 
a Friedlander condensation of a functionalized amino aldehyde with a  ~-carboline followed by other 
transformations.  A highly efficient synthesis was reported by  Behforouz and co-workers
8  in  1993 
with  an  overall  yield  of 33%  from  known  starting  materials.  The  synthesis  utilized  the  Pictet­
Spengler  condensation  of  7-acetamido-2-formylquinoline-5,8-dione  with  the  methyl  ester  of 
(2RS,3SR)- ~-methyltryptophan followed by hydrolysis.  This general method has been used to form 
mUltiple  lavendamycin  as  well  as  demethyllavendamycin  analogues.  The  introduction  of more 
efficient synthetic methods has allowed for the discovery of more useful Lavendamycin derivatives 
displaying both high biological activity and low toxicity. 
Results and Discussion 
Nitration of 8-hydroxy-2-methylquinoline (1) (Scheme  1)  with  a mixture of HN03-H2S04  was 
optimized and altered to be implemented into an undergraduate organic chemistry lab (Appendix  I). 
For the lab to  be successful, the reaction time needed to  be cut in half and reactant quantities needed 
to be reduced nearly 60%.  In reducing the previous amount of HN03/H2S04 (9: 1) solution, the same 
yields were obtained in equal purity.  To shorten the reaction, no ice bath was used during the addition 
of the 8-hydroxy-2-methylquinoline to the acid solution.  Not only did this require an hour shorter 
reaction time but also gave a more pure product. 
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Compound 2 was reduced (Scheme 2) with hydrogen gas in a Parr shaker under the presence of 
PD/C  5%  in 10% HCI  at room temperature for  24 h.  It was  also determined that with addition of 
acetic,  butyric,  or boc  anhydrides in the  presence of large amounts of sodium acetate  and  sodium 
sulfite, compounds 4-6  can be directly generated from the Parr shaker after reduction.  Many other 
procedures and catalysts such as granulated tin,  SnCh/HCI, Pd/C and formic acid, and  a H2  balloon 
were tried in attempts to reduce compound 2 without the use of the  Parr shaker and thus make the 
second  synthetic  step  possible  in  an  undergraduate  lab  setting.  None  of the  procedures  were 4 
successful  with  our  compound  due  to  either  a  lack  of pure  product  or  the  inability  to  recover. 
Products that could not be recovered were added directly to acylation reaction conditions to no effect. 
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Treatment of  the products with MeOH-H20 (10:1) under reflux effectively hydrolyzed the acyloxy 
groups to produce 4-6.  Oxidation with potassium dichromate in a solution of H20-acetic acid at room 
temperature afforded the acylaminoquinolinediones 7-9.  The 2'-methyl group was converted to  an 
aldehyde with the use of  a Se02-H20 catalyst (Scheme 3) yielding compounds 10-12. 
The boc protecting group was used in hopes of  an easier deprotection at the final step of the total 
synthesis.  Procedures using  boc  anhydride produced low yields,  large amounts of impurities,  and 
often times thick gels that created problems in transition.  While boc protection does show promise as 
we know the reactions are possible, continuing deeper research into the topic was not preferred. 
The tryptophan  methyl  ester was the  first  derivative  used in the  Pictet-Spengler condensation. 
Treating DL-tryptophan hydrochloride with TMSCI in methanol at room temperature afforded a high 
yield  of compound 9.  For the  first  time,  compound  10  was  synthesized  using  the  unneutralized 
hydrochloride salt 9 in moderate yields after slowly heating the compound to reflux in anisole with 
continued reflux for 24 h.  The product was allowed to sit open to air tor an additional 24 h to oxidize 
any lavendamycin molecules that were reduced from the dione to the dihydroxy form.  NMR showed 
moderate  amounts  of dihydroxy  compound  still  remaining  in  the  solid.  To  create  a  more  pure 
product,  the  reaction  was  then  initiated  open  to  air  instead  of under  argon,  but  the  amount  of 
dihydroxy compound was comparable to that ofthe reaction under argon. 
Attention  was  then  shifted  to  the  demethyllavendamycin  amide  8.  Using  the 
demethyllavendamycin methyl ester products previously produced, it was shown by NMR that the 
ester could be converted to the amide with treatment of 2M NH3 in methanol and stirring for 24  h. 
Attempts at producing 8 proved that using the 7  N-butyramidoquinolinedione was much more reactive 
than the 7  N-acetamidoquinolinedione.  The problem still remained that not all product was oxidized 
back to  the dione form.  Bubbling compressed air through 8  in acetone for  24  h had an undesired 
effect worse still than allowing the oxidation to occur under ambient conditions.  A new procedure of 5 
treating 8 with DDQ in THF for 24 h afforded a completely oxidized product without a significant 
loss ofyield.  The deprotection of  the product with 70% H2S04 yielded pure compound 9 in low yield 
and new procedural methods have yet to be tested to increase the yield. 
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A  new lavendamycin derivative of interest is the  7'-methoxy compound 20.  The  previously 
synthesized  methoxyquinolinedione  17  was  synthesized  in  the  highest  yield  from  the 
dichloroacetamidodione by treatment with dry methanol and H2S04 at 60°C for 24 h  (Scheme 4). 
Tests on conversion to 2-formyl-7-methoxyquinoline-5,8-dione 19  is currently underway.  Treating 
previously  synthesized  6  with  dry  methanol  and  H2S04 at  60°C for  24h  (Scheme  5)  yielded 
compound 18  in high yields.  Trifluoroacetic  acid  was  then added to  the  product  to  the  desired 
compound 19 in a moderate yield.
9  7-Methoxydemethyllavendamycin amide (20) was synthesized 
with tryptophan amide and 2-Formyl-7-methoxyquinoline-5,8-dione in anisole and was allowed to 
reflux for 24 h resulting in a moderate yield (58%) in high purity. 
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Experimental Section 
General Procedure 
2-Chloroethanol was dry distilled from CaS04 in the presence of Na2C03  and stored in a dark area. 
Triethylamine was refluxed under the presence of CaH2 with argon protection for 2 h, distilled, and 
stored in  a dark area.  Tryptophan hydrochloride salts  were neutralized with  14% NH40H in ethyl 
acetate.  All other materials were purchased or previously prepared in our laboratory.  Selected NMR 
spectra are attached in the appendix (Appendix 2). 
8-Hydroxy-2-methyl-5,7-dinitroquinoline (2).  A solution of concentrated nitric acid (21  mL) 
and concentrated sulfuric acid (9  mL) was  chilled to  0 °C  in a  100  mL  round-bottomed flask.  8­
Hydroxy-2-methylquinoline (4.060 g,  25.5  mmol) was added portion wise over 30 minutes and the 
solution was allowed to stir for an additional hour at room temperature.  The dark brown solution was 
added to  100 mL ice/water and the bright yellow solid was collected by vacuum filtration.  The solid 
was allowed to  dry overnight giving 2.39 g (38%).  IH NMR (DMSO-d6)  02.95 (s, 3H), 8.15 (d, J 
8.9 Hz, IH), 9.21  (s, IH), 9.67 (d, J  8.9 Hz, IH). 
5,7-Diamino-8-hydroxy-2-methylquinoline  Dihydrochloride  (3).  To  a  500  mL  Parr 
hydrogenation bottle, 8-hydroxy-2-methyl-5,7-dinitroquinoline (8.99 g,  3.6 mmol) and 5% Pd/C (2.0 
g)  were suspended in  135  mL water and  15  mL concentrated hydrochloric acid.  The mixture was 
shaken on the hydrogenator for 22 h at  41  psi.  The resulting dark red solution was vacuum filtered 
and the filtrate evaporated in vacuo  to  give a burnt orange solid weighing 8.14  g (86%).  'H NMR 
(DMSO-d6)  0 2.73  (s, 3H), 3.8-5.4 (br s,  IH), 6.48 (s,  IH), 7.08 (d, J  8.0 Hz,  IH), 8.64 (d, J =  8.0 
Hz,IH). 
5,7N-Diacetamido-8-hydroxy-2-methylquinoline  (4).  A  solution  of 2  (3.15  g,  12.0mmol), 
sodium sulfite (5 g), sodium acetate (10 g), and 50 mL water was added to a 250 mL round-bottomed 
flask.  Acetic anhydride (35 mL) was added dropwise over an hour in an ice bath and the reaction was 
allowed to  stir for an additional  1.5  h.  The precipitate was collected via vacuum filtration and the 
filtrate was condensed to  1;4  of the original volume in vacuo.  Additional acetic anhydride (6.5  mL) 
was added dropwise over 15  minutes in an ice bath and 50 mL of water was added to  allow proper 
stirring.  The solid was  vacuum  filtered  and dried in vacuo overnight to  give  2.90 g (77%).  The 
product was proven to  be 5,7-diacetamido-8-acetoxy-2-methylquinoline via NMR.  Treatment of this 
product  with  181.5  mL  MeOH-H20 (l0: 1)  under reflux  for  30  min  and  then  evaporation of the 
solution produced 2.14 g (86%).  'H NMR (DMSO-d6)  0 2.12 (s,  3H), 2.14 (s, 3H), 2.7 (s, 3H), 7.37 
(d, J= 8.8 Hz, IH), 8.03 (s,  IH), 8.14 (d, J  8.8 Hz, IH), 9.57 (s,  IH), 9.79 (s,  IH). 
5,7-Bis[(tert-butoxycarbonyl}amino]-8-hydroxy-2-methylquinoline (6).  In an oven dried 250 
mL 2-necked round-bottomed flask with argon balloon and addition funnel, was added 5,7-diamino-8­
hydroxy-2-methylquinoline dihydrochloride (3.0 g,  11.45 mmolj, DMF (225 mL), sodium acetate (12 
g),  and  sodium  sulfite  (6  g).  The  solution  was  stirred  at  room  temperature  and  di-tert-butyl 
dicarbonate (10.55 mL, 45.9 mmol) was added dropwise over 30 minutes.  The solution was allowed 
to stir for  5 h at room temperature.  A large amount of salt was vacuum filtered and washed with 
DMF.  The filtrate was poured into 750 mL ice-water (2: 1) and left to settle overnight.  The solid was 
filtered and both the solid and the filtrate were put back in the refrigerator overnight.  The filtrate was 
filtered and the two solids were combined and dried in vacuo to yield a tan/brown solid (2.86 g).  The 
product was dissolved in 130 mL methanol/H20 (10: 1) in a 250 mL round-bottomed flask and heated 
under reflux for 5.5 h.  The solution was dried in vacuo and allowed to  dry overnight under vacuum 
yielding 1.86 g (74%). 7 
7N-Acetamido-2-methylquinoline-5,8-dione  (7).  To  a  stirred  suspension  of  5,7­
diacetramido-8-hydroxy-2-methylquinoline (4.08 g,  14.9 mmol) in 180 mL of glacial acetic acid was 
added a solution of potassium dichromate (13.15  g,  44.7 mmol) in  171  mL of water. The resulting 
dark mixture was allowed to stir for 21  h and then extracted with dichloromethane (200 mL,  150 mL, 
4 x 50 mL).  The combined organic extracts were washed with 3% sodium bicarbonate solution (2  X 
100 mL). The aqueous layer was extracted with 2 x 50 mL of dichloromethane, added to the original 
extracts,  and  dried  (MgS04).  The  solution  was  evaporated  in  vacuo  to  condense  to  ~ volume. 
Hexanes was added to precipitate the product.  The crystals were collected via vacuum filtration to 
give 0.92 g (25%).  IH NMR (CDCI3) & 2.30 (s, 3H), 2.75 (s,  3H), 7.55 (d, J =  8.0 Hz,  IH), 7.90 (s, 
IH), 8.29 (d,  8.0 Hz, IH), 8.38 (br s, 1H). 
7-[(tert-butoxycarbonyl)amino]-2-methylquinoline-5,8-dione  (9).  In  a  100  mL  round-
bottomed flask 5,7-dibocamido-8-hydroxy-2-methylquinoline (606 mg,  1.56 mmol) was dissolved in 
glacial acetic acid (30 mL).  Seperately, potassium dichromate (1.40 g) was dissolved in water (16.5 
mL).  The solutions were combined and stirred  giving a yellow precipitate that soon disappeared. 
After  the  reaction  was  complete  water  (48  mL)  was  added  and  the  solution  was  extracted  with 
dichloromethane (3  x 60  mL).  The organic layer was washed with brine  solution (2  x 18  mL) and 
dried with magnesium sulfate for 3 h.  The solution was concentrated to a red/orange liquid in vacuo. 
Ice was added to precipitate a yellow solid which was filtered and washed with water yielding 190 mg 
(42%). 
7N-Acetamido-2-formylquinoline-5,8-dione (10).  A three-necked 25  mL round-bottomed flask 
and  glassware  for  reflux  was  dried  in  the  oven.  To  the  dried  flask  was  added  7-acetamido-2­
methylquinoline-5,8-dione (460 mg, 2 mmol), selenium dioxide (255 mg, 2.5  mmol), and 7 mL  dry 
distilled dioxane.  The mixture was heated to reflux under argon.  After refulx began, 0.25 mL water 
was  added via syringe.  The solution was allowed to stir in a 116°C oil  bath for  16 h.  Additional 
selenium dioxide (8.85  mg,  0.089 mmol) and water (2  drops) were added to  complete the reaction. 
The solution was allowed to stir for 4 h.  To the solution was added 4 mL  and refluxed for 5 more 
minutes.  The selenium was  carefully vacuum filtered  hot through a celite cake.  The filtrate  was 
dissolved in 100 mL dichloromethane and extracted with 10 mL saturated NaCI solution.  The organic 
layer was extracted with 2 x 10 mL 3% sodium bicarbonate solution.  The solution was allowed to dry 
overnight with MgS04, vacuum filtered, and dried in vacuo to give 250 mg (51 %).  IH NMR (CDCh) 
&2.33 (s, 3H), 8.05 (s,  IH), 8.31  (d, J  8.0 Hz,  IH), 8.43  (br s,  IH), 8.62 (d, J= 8.0 Hz, IH),  10.29 
(s,  IH). 
7-[(tert-butoxycarbonyl)amino]-2-formylquinoline-5,8-dione (12).  To a 25  mL three-necked 
round-bottomed  flask  was  added  7-bocamido-2-methylquinoline-5,8-dione  (510  mg,  1.76  mmol), 
selenium dioxide  (233  mg,  2.09 mmol), and 7 mL distilled dioxane via syringe.  The mixture was 
heated to reflux under argon and water (0.25 mL) was added via syringe.  The solution was allowed to 
stir under reflux for 24 h at  115°C.  After the reaction was complete, selenium dioxide was removed 
by filtering hot through a celite cake.  The filtrate was dissolved in 100 mL dichloromethane and was 
extracted  with  3%  sodium  bicarbonate  (2  x  15  mL).  The  organic  layer was  washed  with  brine 
solution (10 mL) and dried overnight with magnesium sulfate.  The mixture was vacuum filtered and 
evaporated in vacuo yielding 304 mg crude product (57%). 
7N-Butyrylamidodemethyllavendamycin  Amide  (13).  Tryptophan  amide  (112.3  mg,  0.553 
mmol) was dissolved in 221  mL anisole in a 500 mL round-bottomed flask under argon protection.  7­
Butyramido-2-formylquinoline (150.5  mg,  0.553  mmol)  was  added  and  the  resulting  mixture  was 
slowly heated to reflux over a 3 h period.  The solution was then allowed to reflux overnight (23.5 h) 
and then sit open to air another night. The dull yellow solid was collected via vacuum filtration and 8 
washed with a small amount of acetone and then ether.  The filtrate was condensed to  1/3 volume in 
vacuo and chilled in the  freezer overnight.  The solid was filtered,  washed, and combined with the 
previously collected solid to yield 197.4 mg (79%).  IH NMR (DMSO-d6) 8 0.95 (t, ] = 7.3 Hz, 3H), 
1.64 (quintet,]= 7.3  Hz, 2H), 2.64 (t,]  7.3 Hz, 2H), 7.41  (dd,]  8.2,7.9 Hz,  IH), 7.65-7.77 (m, 
2H), 7.82 (s,  IH), 8.47 (d,]  =  8.2 Hz,  IH), 8.51 (d,]  = 7.9 Hz, 1H), 9.04 (s,  IH), 9.45 (d,]  8.2 Hz, 
IH), 10.16(s, IH), 11.92 (brs, IH). 
Demethy11avendamycin  Amide  (15).  7-Butyramido-demethyllavendamycin  amide  (66.8  mg, 
0.144 mmol) was placed in a 25 mL two-neck round-bottomed flask under Argon protection.  A 70% 
solution of sulfuric acid (3.5 mL) was added dropwise, and the homogeneous mixture was stirred and 
heated at 60°C in an oil bath for 6 h.  The dark red solution was cooled to 0 °C and then added to 35 
mL of ice-water.  The mixture was carefully basified to pH = 8 with a saturated solution of sodium 
carbonate.  The solution was evaporated in vacuo to dryness and then water (35  mL was added and 
stirred.  The black solid was collected by vacuum filtration and washed with water.  Drying under 
vacuum gave 7.9 mg (14 %).  IH NMR (DMSO-d6)  8 5.96 (s,  IH), 7.41 (t,]= 7.3  Hz, IH), 7.60-7.74 
(m, 2H), 7.78 (d,]  =  8.0 Hz,  IH), 8.46 (d,]  8.0 Hz, 1  H), 8.52 (d,]  =  7.3 Hz, IH), 8.60 (s, IH), 9.06 
(s,  IH), 9.44 (d,]  8.0 Hz,  IH), 12.00 (br s,  IH). 
Tryptophan  Methyl  Ester  Hydrochloride  (16).  DL-Tryptophan  Hydrochloride  (5.11  g,  25 
mmol) was added in a 100 mL round-bottomed flask.  Chlorotrimethylsilane (6.32 mL, 50 mmol) was 
added  slowly and  stirred with a magnetic stirrer.  Methanol  (25  mL) was added and the  resulting 
solution was stirred at room temperature overnight (24  h).  The white precipitate was collected via 
vacuum filtration yielding 5.32 g (98%).  IH NMR (D20) 8 3.48 (t,]  7.0 Hz, 2H), 3.79 (s, 3H), 4.44 
(t,]  =  6.6 Hz,  IH), 7.19 (t,]  = 7.0 Hz, IH), 7.25 (t,]  = 7.0 Hz, IH), 7.30 (s,  IH), 7.52 (d,]  = 8.0 Hz, 
IH), 7.61  (d,]= 7.7 Hz, IH). 
7-Methoxy-2-methylquinoline-5,8-dione (17).  To a stirred solution of 7  N-dichloroactetarnido-2­
methylquinoline-5,8-dione (115  mg, 0.47 mmol) in  15  mL dry methanol was added sulfuric acid  (1 
mL).  The solution was heated at 60°C under argon for 24 h.  The solution was evaporated in vacuo 
and dissolved in dichloromethane (50 mL).  The solution neutralized to ph 7 with saturated sodium 
bicarbonate solution (20 mL).  The organic layer was separated and the aqueous layer was extracted 
with dichloromethane (2  x 50  mL, 2 x 25  mL).  The combined organic layers were extracted with 
brine solution (15  mL),  dried with magnesium sulfate overnight, and  evaporated in  vacuo yielding 
114.9 mg wet product.  lH NMR (CDCh) 8 2.71  (s, 3H), 3.87 (s,  3H), 6.14 (s,  IH), 7.47 (d, ]  =  8.0 
Hz, 1H), 8.24 (d,]= 8.0 Hz, 1H) 
2-(Dimethoxymethyl)-7-methoxyquinoline-5,8-dione  (18).  To  a  stirred  solution  of  7N­
actetamido-2-formylquinoline-5,8-dione  (115  mg,  0.47  mmol)  in  15  mL  dry  methanol  was  added 
sulfuric acid  (1  mL).  The solution was  heated at 60°C under argon for  24  h.  The  solution was 
evaporated in vacuo and dissolved in dichloromethane (50 mL).  The solution neutralized to ph 7 with 
saturated sodium bicarbonate solution (20 mL).  The organic layer was separated and the aqueous 
layer was extracted with dichloromethane (2 x 50 mL, 2 x 25 mL).  The combined organic layers were 
extracted with brine solution (15  mL),  dried with  magnesium  sulfate  overnight, and evaporated in 
vacuo yielding 140.6 mg (77%).  IH NMR (CDCh) 8 3.40 (s, 6H), 3.88 (s, 3H), 5.45 (s,  IH), 6.18 (s, 
IH), 7.89 (d,]= 8.0 Hz, IH), 8AO(d,]  8.0 Hz,  IH). 
2-Formyl-7-methoxyquinoline-5,8-dione  (19).  To  1-(dimethoxymethyl)-7 -methoxyquinoline­
5,8-dione (144.3  mg,  0.55  mmol) was  added trifluoroacetic acid (4.5  mL) under argon protection. 
The solution was allowed to  stir at  room temperature for 2 h.  The resulting dark red solution was 
dissolved  in  dichloromethane  (50  mL)  and  carefully  neutralized  to  pH  7  with  saturated  sodium 
bicarbonate solution (30 mL).  The aqueous layer was again extracted with dichloromethane (2  x 15 9 
mL).  The combine organic layers were washed with brine solution (15 mL) and evaporated in vacuo 
yielding 80 mg (67%).  lH NMR (CDCl}) S 3.99 (s,  3H), 6.34 (s,  IH), 8.30 (dd, J = 8.0,0.7 Hz, IH), 
8.63 (dd, J=8.0, 0.7 Hz, IH), 10.31 (d, J  0.7 Hz, 1H). 
7-Methoxydemethyllavendamycin Amide (20).  Tryptophan amide (mg, mmol) was dissolved in 
150  mL  anisole  in  a  250  mL  round-bottomed  flask  under  argon  protection.  7-Butyramido-2­
formylquinoline ( mg, mmol) was added and the resulting mixture was slowly heated to reflux over a 
3 h period.  The solution was then allowed to reflux overnight (22 h) and then sit open to air another 
night. The dull yellow solid was collected via vacuum filtration and washed with a small amount of 
acetone and then ether.  The filtrate was condensed to 1/3 volume in vacuo and chilled in the freezer 
for 4 h.  The solid was filtered and washed with acetone then ether yielding 83.7 mg (58%).  lH NMR 
(DMSO-d6)  (5  3.96 (s, 3H), 6.51  (s, 1H), 7.40 (t, J  7.7, 1H), 7.68-7.73 (m, 2H), 7.82 (d, J  8.0,lH), 
8.50 (d, J  8.0, 2H), 8.60 (s, 1H), 9.05 (s, 1H), 9.45 (d, J= 8.3, 1H), 11.92 (s, 1H). 
CBZ-Tryptophan p-Hydroxyethyl Ester (21).  In a dried  100 mL round-bottomed flask,  cbz­
tryptophan (1.02 g, 3.0 mmol) and butyl ether (18 mL, 106 mmol) were added under argon protection. 
The  distilled  triethylamine  (0.4  mL)  and  2-chloroethanol  (0.4  mL)  were  added via syringe.  The 
mixture was stirred and heated under reflux for 5 h.  The solution was evaporated in vacuo and ethyl 
acetate was added to precipitate the triethylammonium chloride salt.  The mixture was left to cool in 
the refrigerator overnight.  The white solid was  filtered  and washed with a small  amount of ethyl 
acetate.  The filtrate was extracted with 5% sodium bicarbonate solution (5 mL) and water (3 x 5 mL) 
until the aqueous layer was neutral pH.  The organic layer was dried with magnesium sulfate for 2h, 
evaporated in vacuo, and allowed to dry under vacuum for 3 days at 40-50 °C yielding 733 mg (64%). 
Tryptophan p-Hydroxyethyl Ester (22).  To a 100 mL round-bottomed flask containing N-cbz­
tryptophan  ~-hydroxyethyl ester (733  mg,  1.9  mmol), ammonium formate (395 mg, 6.3  mmol) and 
PdlC  10% (338 mg) were added under argon protection.  DMF (35 mL) was added via syringe along 
with a magnetic stirrer.  The reaction was stirred at room temperature for  4.5  h.  The solution was 
vacuum filtered through a celite filter cake and washed with ethyl acetate.  The filtrate was evaporated 
in vacuo and allowed to dry under vacuum over the weekend yielding 379 mg (80%). 
7N-Acetamidodemethyllavendamycin  p-Hydroxy-ethyl  Ester  (23).  7N-Actemido-2­
formylquinoline-5,8-dione (120.81  mg,  0.05  mmol) and anisole (206 mL) was placed in a 500 mL 
three-neck round-bottomed flask equipped with a Dean-Stark trap and pressure equalization dropping 
funnel under argon.  The solution was heated in an oil bath to 80°C over 30 minutes.  Tryptophan~­
hydroxyethyl ester (164 mg, 0.66 mmol) was dissolved in 9.9 mL DMF and added dropwise over 40 
minutes.  The solution was heated slowly to 160°C over 5.5 h.  The solution was allowed to chill in 
the freezer overnight open to the air.  The solid was collected via vacuum filtration yielding 76.3 mg 
crude product.  Mixed with the desired product was the reduced dihydroxydione compound. 
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Dinitration of  8-Hydroxy-2-methylquinoline 
(an electrophilic aromatic substitution) 

Experiment 15.4X (similar to nitration of  bromo  benzene from Gilbert & Martin) 

Background Reading  J  Org.  Chern.  1996,61, 6552-6555 

Reaction: 
Procedure: 
8-Hydroxy-2-methyl-5,7-dinitroquinoline. HN03 (10 mL) in a 125mL Erlenmeyer flask was cooled 
in an ice/water bath.  H2S04 (5  mL) was carefully added to the flask with continued cooling and the 
solution magnetically stirred (the flask needs to be in the bottom of  the beaker with a little ice water). 
Over  30  minutes;  continuous,  portion-wise  addition  of 8-hydroxyquinaldine  (aka:  8-hydroxy-2­
methylquinoline, 4.06 g) was done with a spatula (slow enough to avoid the brown gas from escaping 
the flask).  Any sample on sidewalls is  pushed down into  flask  with glass rod.  The ice-bath was 
removed and the mixture was allowed to stir at room temperature for at least one hour.  The solution 
is  cautiously poured into a 250 mL  beaker containing  100  grams of ice/water (111)  with vigorous 
stirring (invert flask on ring stand to let it drip for several minutes). The bright yellow precipitate was 
collected  by  vacuum  filtration,  washed  thoroughly  with  ice-cold  DI  water (2  x  25  mL,  rinse  the 
reaction flask into filter), washed meticulously with diethyl ether (3  x 10 mL, remove vacuum hose 
and let it soak for one minute each time), and air-dried until next laboratory to give the product.  Soap 
and brush will be needed to clean yellow residue from glassware. 
IH NMR (DMSO-d6)  89.67 (d, J= 8.9 Hz, IH), 9.21  (s, IH), 8.15 (d, J = 8.9 Hz, IH), 2.95 (s, 3H). 
We will obtain the mass and NMR spectra of our products. Do not obtain melting point!!! (mp 296­
300°C) 

Samples will be collected for use in the cancer research project. 

FYI:  HN03  -16M 

Safety alert on page 504 from Gilbert & Martin. 
concentrated sulfuric acid!  concentrated nitric acid! 
Exercises: 
1.  Show the resonance forms of  the intermediate that support nitration occurring at position 7 (o-/p-). 
2.  Show the resonance forms ofthe intermediate that oppose nitration at position 6 (meta). 
3.  Show the resonance forms ofthe intermediate that oppose nitration at position 4 (other ring). 13 
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